Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 17, 2013, Pages 5480-5487

  Park, Hye Ri ^a   Kim, Jiyoon ^a,b   Kim, Taekeun ^a   Jo, Seonmi ^a   Yeom, Miyoung ^a,b   Moon, Bongjin ^b   Choo, Il Han ^c   Lee, Jaeick ^a   Lim, Eun Jeong ^a   Park, Ki Duk ^a   Min, Sun Joon ^a   Nam, Ghilsoo ^a   Keum, Gyochang ^a   Lee, C Justin ^a   Choo, Hyunah ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Sogang University   (South Korea)

^c Chosun University   (South Korea)

Author keywords

MAO B; Monoamine oxidase B; Oxazolopyridine; Parkinson's disease; Thiazolopyridine

Indexed keywords

2 (2 CHLOROPHENYL) 5 (PIPERIDIN 1 YL)OXAZOLO[5,4 B]PYRIDINE; 2 (2 CHLOROPHENYL) 5 (PIPERIDIN 1 YL)THIAZOLO[5,4 B]PYRIDINE; 2 (2 FLUOROPHENYL) 5 (PIPERIDIN 1 YL)OXAZOLO[5,4 B]PYRIDINE; 2 (3 CHLOROPHENYL) 5 (PIPERIDIN 1 YL)OXAZOLO[5,4 B]PYRIDINE; 2 (3 FLUOROPHENYL) 5 (PIPERIDIN 1 YL)OXAZOLO[5,4 B]PYRIDINE; 2 (4 CHLOROPHENYL) 5 (PIPERIDIN 1 YL)OXAZOLO[5,4 B]PYRIDINE; 2 (4 CHLOROPHENYL) 5 (PIPERIDIN 1 YL)THIAZOLO[5,4 B]PYRIDINE; 2 (4 FLUOROPHENYL) 5 (PIPERIDIN 1 YL)OXAZOLO[5,4 B]PYRIDINE; 2 (4 FLUOROPHENYL) 5 (PIPERIDIN 1 YL)THIAZOLO[5,4 B]PYRIDINE; 2 CHLORO N (2,6 DICHLOROPYRIDIN 3 YL)BENZAMIDE; 2 PHENYL 5 (PIPERIDIN 1 YL)OXAZOLO[5,4 B]PYRIDINE; 2 PHENYL 5 (PIPERIDIN 1 YL)THIAZOLO[5,4 B]PYRIDINE; 3 CHLORO N (2,6 DICHLOROPYRIDIN 3 YL)BENZAMIDE; 5 (AZEPAN 1 YL) 2 PHENYLOXAZOLO[5,4 B]PYRIDINE; 5 CHLORO 2 (2 CHLOROPHENYL)THIAZOLO[5,4 B]PYRIDINE; 5 CHLORO 2 (4 CHLOROPHENYL)THIAZOLO[5,4 B]PYRIDINE; 5 CHLORO 2 (4 FLUOROPHENYL)THIAZOLO[5,4 B]PYRIDINE; 5 CHLORO 2 PHENYLTHIAZOLO[5,4 B]PYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; MONOAMINE OXIDASE B INHIBITOR; N (2,6 DICHLOROPYRIDIN 3 YL) 3 FLUOROBENZAMIDE; N (2,6 DICHLOROPYRIDIN 3 YL) 4 FLUOROBENZAMIDE; N BENZYL 2 PHENYLOXAZOLO[5,4 B]PYRIDIN 5 AMINE; N BENZYL N METHYL 2 PHENYLOXAZOLO[5,4 B]PYRIDIN 5 AMINE; N CYCLOHEXYL 2 PHENYLOXAZOLO[5,4 B]PYRIDIN 5 AMINE; N METHYL 2 PHENYLOXAZOLO[5,4 B]PYRIDIN 5 AMINE; OXAZOLOPYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; THIAZOLOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC 50; MOLECULAR DOCKING; NONHUMAN; PARKINSON DISEASE; STRUCTURE ACTIVITY RELATION;

MAO-B; MONOAMINE OXIDASE B; OXAZOLOPYRIDINE; PARKINSON'S DISEASE; THIAZOLOPYRIDINE;

BINDING SITES; CATALYTIC DOMAIN; DOPAMINE; HUMANS; MOLECULAR DOCKING SIMULATION; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXAZOLES; PARKINSON DISEASE; PYRIDINES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84881376962     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.05.066     Document Type: Article

References (20)

1. L.M.L. de Lau, and M.M.B. Breteler Lancet Neurol. 5 2006 525
2. J. Jankovic J. Neurol. Neurosurg. Psychiatry 79 2008 368
3. D.C. German, K. Manaye, W.K. Smith, D.J. Woodward, and C.B. Saper Ann. Neurol. 26 1989 507
4. G. Gardian, and L. Vecsei Int. J. Clin. Pharmacol. Ther. 48 2010 633
5. S. Fahn Mov. Disord. 23 2008 S497
6. A.W.J. Bach, N.C. Lan, D.L. Johnson, C.W. Abell, M.E. Bembenek, S.W. Kwan, P.H. Seeburg, and J.C. Shih Proc. Natl. Acad. Sci. U.S.A. 85 1988 4934
7. J.K. Mallajosyula, D. Kaur, S.J. Chinta, S. Rajagopalan, A. Rane, D.G. Nicholls, D.A. Di Monte, H. Macarthur, and J.K. Andersen PLoS ONE 3 2008 e1616
8. C.A. Lieu, S.J. Chinta, A. Rane, and J.K. Andersen PLoS ONE 8 2013 e54200
9. P. Levitt, J.E. Pintar, and X.O. Breakefield Proc. Natl. Acad. Sci. U.S.A. 79 1982 6385
10. M. Bortolato, K. Chen, and J.C. Shih Adv. Drug Delivery Rev. 60 2008 1527
11. H.H. Fernandez, and J.J. Chen Pharmacotherapy 27 2007 174S
12. S. Pålhagen, E. Heinonen, J. Hagglund, T. Kaugesaar, O. Maki-Ikola, and R. Palm Neurology 66 2006 1200
13. J.M. Rabey, I. Sagi, M. Huberman, E. Melamed, A. Korczyn, N. Giladi, R. Inzelberg, R. Djaldetti, C. Klein, and G. Berecz Clin. Neuropharmacol. 23 2000 324
14. P. Vezina, E. Mohr, and D. Grimes Can. J. Neurol. Sci. 19 1992 142
15. M.B. Stern, K.L. Marek, J. Friedman, R.A. Hauser, P.A. LeWitt, D. Tarsy, and C.W. Olanow Mov. Disord. 19 2004 916
16. W. Dimpfel, and J. Hoffmann BMC Pharmacol. 11 2011 2
17. Barrow, J.; Harrison, S.; Mulhearn, J.; Sur, C.; Williams, D. L.; Wolkenberg, S. WO 155,017, 2009, A2.
18. J. Kempson, S.H. Spergel, J. Guo, C. Quesnelle, P. Gill, D. Belanger, A.J. Dyckman, T. Li, S.H. Watterson, C.M. Langevine, J. Das, R.V. Moquin, J.A. Furch, A. Marinier, M. Dodier, A. Martel, D. Nirschl, K.V. Kirk, J.R. Burke, M.A. Pattoli, K. Gillooly, K.W. McIntyre, L. Chen, Z. Yang, P.H. Marathe, D. Wang-Iverson, J.H. Dodd, M. McKinnon, J.C. Barrish, and W.J. Pitts J. Med. Chem. 52 2009 1994
19. F. Chimenti, D. Secci, A. Bolasco, P. Chimenti, B. Bizzarri, A. Granese, S. Carradori, M. Yánez, F. Orallo, F. Ortuso, and S. Alcaro J. Med. Chem. 52 2009 1935
20. C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D.E. Edmondson, and A. Mattevi J. Med. Chem. 50 2007 5848